- Home
- SN vs INCY Comparison
SN vs INCY Comparison
Compare SN & INCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SN
- INCY
- Stock Information
- Founded
- SN 1993
- INCY 1991
- Country
- SN United States
- INCY United States
- Employees
- SN N/A
- INCY N/A
- Industry
- SN
- INCY Biotechnology: Commercial Physical & Biological Resarch
- Sector
- SN
- INCY Health Care
- Exchange
- SN Nasdaq
- INCY Nasdaq
- Market Cap
- SN 13.0B
- INCY 13.4B
- IPO Year
- SN N/A
- INCY 1993
- Fundamental
- Price
- SN $110.76
- INCY $68.59
- Analyst Decision
- SN Strong Buy
- INCY Hold
- Analyst Count
- SN 8
- INCY 20
- Target Price
- SN $121.50
- INCY $73.81
- AVG Volume (30 Days)
- SN 1.8M
- INCY 1.8M
- Earning Date
- SN 08-07-2025
- INCY 07-29-2025
- Dividend Yield
- SN N/A
- INCY N/A
- EPS Growth
- SN 133.24
- INCY N/A
- EPS
- SN 3.16
- INCY 0.10
- Revenue
- SN $5,685,049,000.00
- INCY $4,413,226,000.00
- Revenue This Year
- SN $16.68
- INCY $13.48
- Revenue Next Year
- SN $11.56
- INCY $10.35
- P/E Ratio
- SN $35.12
- INCY $713.94
- Revenue Growth
- SN 27.34
- INCY 17.13
- 52 Week Low
- SN $60.50
- INCY $53.56
- 52 Week High
- SN $123.00
- INCY $83.95
- Technical
- Relative Strength Index (RSI)
- SN 74.96
- INCY 52.44
- Support Level
- SN $104.47
- INCY $66.85
- Resistance Level
- SN $108.38
- INCY $70.62
- Average True Range (ATR)
- SN 3.23
- INCY 1.85
- MACD
- SN 1.67
- INCY -0.16
- Stochastic Oscillator
- SN 96.64
- INCY 38.87
About SN SharkNinja Inc.
SharkNinja Inc is a product design and technology company that creates 5-star-rated lifestyle solutions through inventive products for consumers around the world. Its product categories include Cleaning, Cooking, Food Preparation, Home Environment and Beauty products. It sells vacuum cleaners, cooking pots, fryers, hair dryers, etc. The SharkNinja Group is expected to carry on the design, production, marketing, and distribution of the Shark and Ninja brands of small household appliances in North America, Europe and other selected international markets (excluding the Asia Pacific Region and Greater China). Currently, the majority of the revenue is derived from the U.S. market.
About INCY Incyte Corp.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.